Enhancement of adaptive immunity to neisseria gonorrhoeae by local intravaginal administration of microencapsulated interleukin 12

Journal of Infectious Diseases

Volumn 208, Issue 11, 2013, Pages 1821-1829

  Liu, Yingru ^a   Egilmez, Nejat K ^a   Russell, Michael W ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Cytokine therapy; IL 12; Immunity; Microencapsulation; Neisseria gonorrhoeae

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 17; MICROSPHERE; POLYMER; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL CLEARANCE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESPONSE; FEMALE; GONORRHEA; HUMORAL IMMUNITY; IMMUNITY; IMMUNOREACTIVITY; LOW DRUG DOSE; MICROENCAPSULATION; MOUSE; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; REINFECTION; TH1 CELL; TH2 CELL;

CYTOKINE THERAPY; IL-12; IMMUNITY; MICROENCAPSULATION; NEISSERIA GONORRHOEAE;

ADAPTIVE IMMUNITY; ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTIBODIES, BACTERIAL; DISEASE MODELS, ANIMAL; DRUG COMPOUNDING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GONORRHEA; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; MICROSPHERES; NEISSERIA GONORRHOEAE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84888628079     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit354     Document Type: Article

References (38)

1. Russell MW, Hook EW. Gonorrhea. Barrett ADT, Stanberry LR, eds. Vaccines for biodefense and emerging and neglected diseases. London, UK: Academic Press, 2009:963-81.
2. Zhu W, Chen CJ, Thomas CE, et al. Vaccines for gonorrhea: can we rise to the challenge? Front Microbiol 2011; 2:124.
3. World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae, 2012.
4. Hook EW, Handsfield HH. Gonococcal infections in the adult. Holmes KK, Sparling PF, Mårdh PA, et al., eds. Sexually transmitted diseases. New York, NY: McGraw-Hill Health Professions Division, 1999.
5. Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med 2012; 366:485-7.
6. Ram S, Cullinane M, Blom AM, et al. Binding of C4b-binding protein to pora molecular mechanism of serum resistance of Neisseria gonorrhoeae. J Exp Med 2001; 193:281-95.
7. Smith H, Parsons NJ, Cole JA. Sialylation of neisserial lipopolysaccharide: A major influence on pathogenicity. Microb Pathog 1995; 19:365-77.
8. Lewis LA, Burrowes E, Rice PA, Ram S. Interactions of Neisseria with complement. Genco CA, Wetzler L, eds. Neisseria: molecular mechanisms of pathogenesis. Norfolk, UK: Caister Academic Press, 2010.
9. Liu Y, Feinen B, Russell MW. New concepts in immunity to Neisseria gonorrhoeae: innate responses and suppression of adaptive immunity favor the pathogen, not the host. Front Microbiol 2011; 2:52.
10. Liu Y, Russell MW. Diversion of the immune response to Neisseria gonorrhoeae from Th17 to Th1/Th2 by treatment with anti-transforming growth factor β antibody generates immunological memory and protective immunity. M Bio 2011; 2:e00095-11.
11. Liu Y, Islam EA, Jarvis GA, et al. Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-β-dependent mechanisms. Mucosal Immunol 2012; 5:320-331.
12. Liu Y, Liu W, Russell MW. Suppression of host adaptive immune responses by Neisseria gonorrhoeae: role of interleukin 10 and type 1 regulatory T cells Mucosal Immunol. 2013. doi:10.1038/mi.2013.36.
13. Feinen B, Jerse AE, Gaffen SL, Russell MW. Critical role of Th17 responses in a murine model of Neisseria gonorrhoeae genital infection. Mucosal Immunol 2010; 3:312-321.
14. Egilmez NK. Interleukin-12: effector mechanisms and homeostatic counter-regulation. Manjili MH, ed. Cytokines: mechanisms, functions and abnormalities. 1st ed. Hauppauge, NY: Nova Science Publishers, 2011:3-22.
15. Metzger DW. IL-12 as an adjuvant for the enhancement of protective humoral immunity. Expert Rev Vaccines 2009; 8:515-8.
16. Metzger DW. Interleukin-12 as an adjuvant for induction of protective antibody responses. Cytokine 2010; 52:102-7.
17. Boyaka PN, Marinaro M, Jackson RJ, et al. IL-12 is an effective adjuvant for induction of mucosal immunity. J Immunol 1999; 162:122-8.
18. Arulanandam BP, O'Toole M, Metzger DW. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis 1999; 180:940-9.
19. Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun 2003; 71:4780-8.
20. Baron SD, Singh R, Metzger DW. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion. Infect Immun 2007; 75:2152-62.
21. Kumar D, Kirimanjeswara G, Metzger DW. Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague. Clin Vaccine Immunol 2011; 18:1925-35.
22. Cohen J. IL-12 deaths: explanation and a puzzle. Science 1995; 270:908.
23. Hedlund J, Langer B, Konradsen HB, Ortqvist A. Negligible adjuvant effect for antibody responses and frequent adverse events associated with IL-12 treatment in humans vaccinated with pneumococcal polysaccharide. Vaccine 2001; 20:164-9.
24. Egilmez NK, Kilinc MO, Gu T, Conway TF. Controlled-release particulate cytokine adjuvants for cancer therapy. Endocr Metab Immune Disord Drug Targets 2007; 7:266-70.
25. Mathiowitz E, Jacob JS, Jong YS, et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature 1997; 386:410-4.
26. Langer R. Drug delivery and targeting. Nature 1998; 392:5-10.
27. Egilmez NK, Jong YS, Mathiowitz E, Bankert RB. Tumor vaccination with cytokine-encapsulated microspheres. Methods Mol Med 2003; 75:687-96.
28. Jerse AE. Experimental gonococcal genital tract infection and opacity protein expression in estradiol-treated mice. Infect Immun 1999; 67:5699-708.
29. Weigmann B, Tubbe I, Seidel D, et al. Isolation and subsequent analysis of murine lamina propria mononuclear cells from colonic tissue. Nat Protoc 2007; 2:2307-11.
30. Snapper CM, Paul WE. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987; 236:944-7.
31. Airoldi I, Gri G, Marshall JD, et al. Expression and function of IL-12 and IL-18 receptors on human tonsillar B cells. J Immunol 2000; 165:6880-8.
32. Jelinek DF, Braaten JK. Role of IL-12 in human B lymphocyte proliferation and differentiation. J Immunol 1995; 154:1606-13.
33. Thibodeaux DK, Hunter SE, Waldburger KE, et al. Autocrine regulation of IL-12 receptor expression is independent of secondary IFN-γ secretion and not restricted to T and NK cells. J Immunol 1999; 163: 5257-64.
34. Skok J, Poudrier J, Gray D. Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: A feedback regulation of Th1 development. J Immunol 1999; 163:4284-91.
35. Nady S, Ignatz-Hoover J, Shata MT. Interleukin-12 is the optimum cytokine to expand human Th17 cells in vitro. Clin Vacc Immunol 2009; 16:798-805.
36. Watkins SK, Egilmez NK, Suttles J, Stout RD. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol 2007; 178:1357-62.
37. Yu J, Wei M, Becknell B, et al. Pro- And antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity 2006; 24:575-90.
38. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005; 8:369-80.